Merit Medical Systems Inc (MMSI) Stock Price
MMSIStock
$89.20+10.38%52W
Market Cap$5.33B
P/E41.45x
PEG Ratio1.62
Div yield—
Beta0.56
MMSI Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)16.55%
Price vs S&P 500 (4W)5.66%
PEG Ratio1.62
VGM Score64.03
P/E Ratio (Annual)41.45x
MMSI Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.96 | $1.19 | +24.02%(+$0.23) | |
| Q1 2026 | $0.83 | $0.94 | +12.80%(+$0.11) | |
| Q4 2025 | $0.95 | $1.04 | +8.98%(+$0.09) | |
| Q3 2025 | $0.83 | $0.92 | +11.18%(+$0.09) | |
| Q2 2025 | $0.85 | $1.01 | +18.64%(+$0.16) |
MMSI Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.18
4.18
4.18
4.18
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
MMSIMerit Medical Systems Inc | C | B | B | 3.4x | 9.5% | 49.5% | 12.8% | $89.20 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
About Merit Medical Systems Inc
Merit Medical Systems develops and manufactures medical devices for interventional cardiology, radiology, and endoscopy procedures. The Cardiovascular segment generates the majority of revenue, encompassing cardiology and radiology products for treating coronary artery disease, peripheral vascular disease, and other conditions, including embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.